QR Kodea

Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma

Abstract Background TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare but highly heterogeneous renal cell carcinoma (RCC) entity, of which the clinical treatment landscape is largely undefined. This study aims to evaluate and compare the efficacy of different systemic treatments and further...

Deskribapen osoa

Gorde:
Egile Nagusiak: Junjie Zhao, Yanfeng Tang, Xu Hu, Xiaoxue Yin, Yuntian Chen, Junru Chen, Haoyang Liu, Haolin Liu, Jiayu Liang, Xingming Zhang, Jinge Zhao, Sha Zhu, Yuchao Ni, Zhipeng Wang, Jindong Dai, Zilin Wang, Yaowen Zhang, Jin Yao, Ni Chen, Pengfei Shen, Zhenhua H. Liu, Hao Zeng, Guangxi X. Sun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2024-06-01
Saila:Molecular Cancer
Gaiak:
TFE3-rRCC
Fusion partner
ASPSCR1
Immune checkpoint inhibitor
Combination therapy
Molecular correlates
Sarrera elektronikoa:https://doi.org/10.1186/s12943-024-02044-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak